References
- Parker S L, Tong T, Bolden S, et al. Cancer Statistics, 1996. Cancer Statistics 1996; 46: 10–11
- Thigpen J, Blessing J A, Vance R B, et al. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 1989; 16: 58–65
- Thigpen J, Vance R B, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71: 1559–1564
- McKeage M J. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228–44
- Ozols R F, Rubin S C, Dembo A J, et al. Epithelial Ovarian Cancer. J.B. Lippincott, Philadelphia 1992; 731–732
- McGuire W P, Hoskins W J, Brady M F, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6
- Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389–393
- Eisenhauer E A, ten Bokken Huinink W W, Swenertokn K D, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666
- Aravantinos G, Skarlos D V, Kosmidis P, et al. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 1997; 33: 160–163
- Bruzzone M, Catsafados E, Miflietta L, et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology 1996; 53: 349–53
- Gore M E, Levy V, Rustin G, et al. Paclitaxel in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016–1019
- Nardi M, Aloe A, DeMarco S, et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol 1997; 20: 230–232
- Ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–2193
- Creemers G J, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large european phase II study. J Clin Oncol 1996; 14: 3056–3061
- Kudelka A P, Tresukosol D, Edwards C L, et al. A phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552–1557
- Vergote I, Himmelmann A, Frankendal B, et al. Hexamethylmela-mine as second-line therapy in platin resistant ovarian cancer. Gynecol Oncol 1992; 47: 282–286
- Manetta A, MacNeill C, Lyter J A, et al. Hexamethylmelamine as a single second line agent in ovarian cancer. Gynecol Oncol 1990; 36: 93–96
- Schink J, Hanis L, Grosen E, et al. Altretamine an effective salvage chemotherapy after paclitaxel in women with recurrent platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 770a
- Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60–63
- Rose P G, Blessing J A, Mayer A R, et al. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405–410
- Medical Carriers Manual. Drugs and Supplies, HCFA Pub. 6 Section 2049.5 Coverage and Limitations, 2–18.22, 05–96
- Liu G, Franssen E, Fitch M I, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–115
- Bailes J. Health Care Economics of Cancer in the Elderly. Cancer 1997; 80: 1348–1350
- Coleman T. Practical Tips for the Practicing Oncologist. American Society of Clinical Oncology, Alexandria, Va 1997
- Federal Register Fri Nov 22, 1996; Vol. 61(No. 227)
- Doyle C, Stockler M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997; 15: 1000–1007
- Ignoffo R J. Medicare reimbursement for oral antiemetics in management of chemotherapy-induced emesis. Am J Health Syst Pharm 1997; 54: 830–831